Cynthia D. Guy

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu et al. · Hepatology · 2023 · 2.9K citations · Full text

Medicine, Internal Medicine, Pathology +17

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

Jérôme Boursier, Olaf Mueller, Matthieu Barret et al. · Hepatology · 2015 · 1.5K citations

Life Sciences, Microbiology, Pathology +17

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy et al. · The Lancet · 2019 · 765 citations

Medicine, Pharmacology, Pharmacotherapy +9

Increased Fructose Consumption Is Associated With Fibrosis Severity in Patients With Nonalcoholic Fatty Liver Disease

Manal F. Abdelmalek, Ayako Suzuki, Cynthia D. Guy et al. · Hepatology · 2010 · 762 citations

Agriculture, Nutrition, Nutritional Sciences +17